 |
|
The Era of Targeted TherapiesIncreasing Role for Novel Oncologic Drugs in Dermatology
Liliana Montella, MD;
Giovannella Palmieri, MD;
Mario Lacouture, MD
Arch Dermatol. 2007;143(6):788-789.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Cancer treatment entered a new era when it advanced from a time of treatment regimens based only on chemotherapy to targeted therapies developed from an increasing knowledge of pathogenetic mechanisms involved in the biologic characteristics of tumors. This usually translates into increasing therapeutic power, higher rates of activity, better rates of survival, and fewer or different adverse effects compared with conventional treatments. Newly available therapies are essentially divided into 2 classes: monoclonal antibodies and small molecules, or tyrosine kinase inhibitors.
Monoclonal antibodies interact with cell membrane receptors, generally blocking cell regulatory signals induced by natural ligands. Tyrosine kinase inhibitors are molecules designed to block intracellular signaling pathways leading to deregulation of key cell functions such as proliferation and differentiation. A number of antibodies have been approved or are in development for use as therapeutic agents in cancer (eg, cetuximab, bevacizumab, panitumumab, . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED ARTICLE
Imatinib as a Treatment Option for Systemic Non-Langerhans Cell Histiocytoses
Jochen Utikal, Selma Ugurel, Hjalmar Kurzen, Philipp Erben, Andreas Reiter, Andreas Hochhaus, Thomas Nebe, Ralf Hildenbrand, Uwe Haberkorn, Sergij Goerdt, and Dirk Schadendorf
Arch Dermatol. 2007;143(6):736-740.
ABSTRACT
| FULL TEXT
|
